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Abstract To examine the factors that control the extent of
incorporation of Vpr into the virus particles, we utilized an
epitope-tagging approach with Flag (FL) as the epitope for
quantitation. We generated expression plasmids containing Vpr-
FL and Vpr E21,24P-FL and also HIV-1 proviral DNA
containing Vpr-FL (NL-Vpr-FL). Immunoblot analysis using
Flag antibodies revealed that virus particles derived from co-
transfection of NL-Vpr-FL and Vpr-FL showed an enhanced
level of Vpr-FL in comparison to NL-Vpr-FL derived virus.
These results suggest that the amount of incorporation of Vpr
into the virus particles is flexible and may be modulated by its
expression level in cells.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
The biochemical analysis of virus particles encoded by the
HIV-1 genome revealed the presence of both structural pro-
teins, common to all retroviruses, and non-structural proteins
of viral origin [10,15,28]. The structural proteins in the virus
particles are Gag, Gag-pol and the Env [8,23]. The Env pro-
tein reaches the cell surface through the secretory pathway
and both Gag and Gag-pol arrive at the cell membrane
with the help of a myristylation signal through an unknown
mechanism [23]. The non-structural proteins present in the
virus particles include Vif, Vpr, and Nef [2^4,6,9,10,18,24,
28,39,40,53]. Of the non-structural proteins, only Nef pos-
sesses a myristylation signal similar to Gag and Gag-pol
[28]. Interestingly, the non-structural proteins have been
shown to be present in di¡erent amounts in the virions raising
questions about the mode of incorporation of these proteins
[16,19]. In this regard, recent studies showed that Vif and Nef
are incorporated into the virus particles by a non-speci¢c
mechanism [3,4,19,44,49]. A recent study reported that Vif is
not present in highly puri¢ed virions [12]. On the other hand,
Vpr incorporation is mediated by a speci¢c mechanism involv-
ing Vpr and Gag [5,26,27,31,40].
In an e¡ort to study the underlying factors that contribute
to the incorporation of non-structural proteins into the virus
particles, we have been conducting studies on Vpr for the past
several years. Work from our laboratory and others showed
the importance of the putative helical domains in Vpr for its
incorporation into virus particles [13,14,32^37,45,52]. With
respect to the speci¢city of Vpr for HIV-1 virions, it was
shown that Vpr requires the p6 region of Gag, as the deletion
of this domain completely eliminated its incorporation
[5,25,26,31]. Further, the addition of this motif to Moloney
murine leukemia virus Gag enabled the incorporation of Vpr
into the virus particles [26]. Despite a wealth of date available
on Vpr, the information regarding the number of molecules of
Vpr within the virus particles is not clear. The studies reported
in the literature indicate contradictory data regarding the
number ranging from 250^2500 molecules [9,25].
Based on the speci¢c incorporation feature of Vpr for
HIV-1 virions, it has been considered as a potential carrier
of proteins/peptides of interest into the virus particles
[17,25,38,43,48,50,51]. In this regard, it was shown that the
generation of a chimeric Vpr containing Vpr and HIV-1 pro-
tease cleavage recognition sequences, resulted in the inhibition
of virus replication [43]. The e¡ectiveness of this as a thera-
peutic approach depends on the incorporation of chimeric
Vpr into the virus particles in the presence of wild-type Vpr.
Hence, a central question regarding this approach is whether
incorporation of Vpr with respect to the number of molecules
is rigid or the extent of incorporation can be modulated by
the expression level of Vpr in cells. To explore this, we have
employed HIV-1 proviral DNA containing Vpr-FL and an
expression plasmid of the same in which Vpr-FL coding se-
quences are under the control of the immediate early pro-
moter of human cytomegalovirus. The analysis of virus par-
ticles indicated that the extent of incorporation of Vpr can be
altered with the expression level of Vpr in cells.
2. Materials and methods
2.1. Construction of Vpr-FL expression plasmid and generation of
HIV-1 proviral DNA containing Vpr-FL
Vpr-FL and Vpr E21,24P-FL expression plasmids were generated
by using PCR methodologies [33,42,43]. The sequences corresponding
to the Flag epitope (DYKDDDDK) [7] were incorporated in the 3P
primer. DNA fragments were ampli¢ed using the proviral clone NL4-
3 as the template and cloned into the pCDNA3 vector between Hin-
dIII and XhoI restriction enzyme cleavage sites. The coding sequences
in the vector are £anked by the human cytomegalovirus (CMV) im-
mediate early promoter and T7 promoter sequences upstream and
bovine growth hormone poly(A) signal sequences downstream. Vpr-
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FL coding sequences were ampli¢ed with the primer pair designated
HKVpr(+) forward, 5P-TCTAGAAGCTTGCCGCCACCATGGAA-
CAAGCCCCAGAAGAC-3P and Vpr-FL(3) reverse, 5P-CCCCCC-
TCGAGCTACTTGTCATCGTCGTCCTTGTAGTCGGATCTACT-
GGCTCCATT-3P. The primers used for point mutations in Vpr
E21,24P-FL were (the nucleotides di¡ering from the parent plasmid
are shown boldface) forward, 5P-CCGCTTTTACCGGAGCTTAA-
GAATGAAGCTGTGAGA-3P and reverse, 5P-AAGCTCCGGTA-
AAAGCGGTAGTGTCCAGTCATTGTA-3P. All recombinant plas-
mids were veri¢ed by restriction enzyme cleavage and DNA sequence
analysis.
Vpr-FL containing pCDNA3 vector was cleaved with EcoRI and
XhoI to generate the fragment for insertion into proviral DNA (NL4-
3) cleaved at EcoRI and SalI as described [43]. The proviral DNA
designated NLvVpr lacks Vpr expression due to a frameshift muta-
tion (close to EcoRI recognition site) in the coding sequences.
2.2. In vitro transcription/translation and radioimmunoprecipitation
analysis of proteins
The coupled T7 transcription/translation system (Promega, Madi-
son, WI, USA) was used for characterizing the expression of the
recombinant clones. Incubation conditions were followed according
to the manufacturer’s instructions. Radioimmunoprecipitation analy-
sis (RIPA) of in vitro translated proteins was carried out using poly-
clonal sera to Vpr and the Flag epitope [43].
2.3. Generation of virus particles directed by HIV-1 proviral DNA
HIV-1 proviral DNA (wild-type and modi¢ed in Vpr coding se-
quences) (5 Wg) was transfected into RD cells as described [43]. Virus
particles released into the culture medium were harvested 72^120 h
post-transfection and quantitated by p24 antigen assay using an ELI-
SA (Organon Teknika, Durham, NC, USA).
2.4. Immunoblot analysis
Virus containing culture supernatants were pre-cleared for 10 min
at 10 000 rpm and subsequently spun at 40 000 rpm for 3 h using
sucrose density gradient centrifugation. Virus pellets were lysed with
phosphate bu¡ered saline (PBS) containing 0.05% Triton X-100. Sam-
ples, normalized on the basis of p24 antigen values, were run on 10%/
16% SDS^PAGE gel followed by transfer to a nitrocellulose mem-
brane [42]. After each antibody incubation, blot was washed several
times with TTBS (20 mM Tris, 500 mM NaCl, 0.05% Tween 20,
pH 7.5) (Bio-Rad). The CDP-Star1 (Promega) was used as the chem-
iluminescent substrate in a non-radioactive detection system.
2.5. Quanti¢cation by densitometry
The intensity of the bands obtained through immunoblot analysis
was used for calculating the extent of incorporation of Vpr. Blots
were scanned and densitometric analysis was performed using the
Image Quant program (Molecular Dynamics) as described [42].
3. Results
3.1. Construction and expression of chimeric Vpr-FL
The Vpr coding sequences were cloned into a plasmid vec-
tor which contains the immediate early promoter derived from
human cytomegalovirus. To enable the detection and quanti-
tation of Vpr, an epitope tag approach was utilized. Flag
epitope (DYKDDDDK), for which polyclonal and monoclo-
nal antibodies are commercially available, was added to the
C-terminus of Vpr (Fig. 1), using PCR, to generate Vpr-FL.
We have also generated a mutant Vpr in which the glutamic
acid residues located at positions 21 and 24 of Vpr were re-
placed with proline residues. The mutant Vpr containing pro-
line residues showed a drastic reduction in its ability to be
incorporated into the virus particles [34]. Hence, using mutant
Vpr would serve as a control with respect to speci¢c incorpo-
ration of Vpr. The backbone plasmid vector, pCDNA3, was
used as a negative control. To examine the protein directed by
the Vpr-FL and Vpr E21,24P-FL plasmids, an in vitro tran-
scription/translation system was used. The protein synthesized
in vitro was immunoprecipitated using antiserum against Vpr
(Fig. 2A) and the Flag epitope (Fig. 2B). The analysis of the
proteins on SDS^PAGE showed that Flag antibodies detected
a protein of 14 kDa in size which was also reactive to Vpr
anti-serum. As expected, a band corresponding to the protein
in the same molecular weight range was not detected with the
backbone pCDNA3 vector in the reaction.
3.2. Assessment of the speci¢city of incorporation of Vpr into
the virus particles
The speci¢c incorporation of Vpr directed by HIV-1 is a
prerequisite for determining the amount of Vpr present within
the virus particles. We considered the possibility that non-
speci¢c associations of Vpr with contaminating vesicles in
the virus preparation may lead to a wrong estimation. To
rule this out, we utilized wild-type and mutant Vpr in co-
transfection experiments with HIV-1 proviral DNA lacking
Vpr expression (NLvVpr). The immunoblot analysis of virus
particles showed that virion incorporation was observed for
Fig. 1. Schematic representation of Vpr and Vpr-FL and Vpr
E21,24P-FL. The sequences corresponding to the Flag epitope are
added to the 3P end of Vpr.
Fig. 2. Radioimmunoprecipitation analysis of the protein generated
through in vitro transcription/translation system using polyclonal
sera to (A) Vpr, and (B) Flag epitope. M, molecular weight markers
(kDa); lane 1, pCDNA3 ; lane 2, Vpr-FL; lane 3, Vpr E21,24P-FL;
lane 4, Vpr.
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wild-type Vpr and that mutant Vpr failed to incorporate into
the virus particles under the conditions used (Fig. 3). These
experiments clearly indicate that there is not any non-speci¢c
association of Vpr-FL with the virus particles, as reported for
wild-type Vpr [34,52].
3.3. Generation of HIV-1 proviral DNA containing Vpr-FL
We have adapted a strategy which was successfully used in
an earlier study by our group [43], to introduce chimeric Vpr
sequences into HIV-1 proviral genome. The 3P end of the Vpr
coding region contains a unique cleavage site for the restric-
tion enzymes EcoRI and SalI, which are located at residues 62
and 76, respectively. DNA sequence analysis reveals an over-
lap of Vpr and Tat involving only 24 nucleotides at the 3P end
of Vpr. Considering this, an insertion of EcoRI-XhoI frag-
ment from the Vpr-FL expression plasmid into the proviral
DNA cleaved with EcoRI and SalI (NL-Vpr-FL) may not
create an undesirable e¡ect. In this scheme, even though
20 amino acid residues at the C-terminus of Vpr are dupli-
cated, the second copy will not be translated because of a
termination codon following the ¢rst copy.
3.4. Analysis of epitope-tagged Vpr in the virus particles
To monitor the extent of incorporation of Vpr-FL into the
virus particles in relation to the amount of Vpr-FL present in
cells, we have considered a strategy involving co-transfection
of NL-Vpr-FL proviral DNA with Vpr-FL expression plas-
mid. The analysis of virus particles derived from the co-trans-
fection of DNA into cells may reveal one of two possible
scenarios. It is likely that the amount of Vpr is low in cells
when Vpr is expressed in the context of HIV-1 proviral DNA.
The low amount of Vpr-FL in the virus particles may be
re£ective of the level within the cells (Fig. 4). On the other
hand, the expression of Vpr via the CMV immediate early
promoter could lead to an increased level of Vpr inside the
cells. The increased availability of Vpr may result in an en-
hanced level of Vpr-FL incorporation into the virus particles
(Fig. 4). Alternatively, the incorporation remains constant,
showing no correlation with the level of Vpr inside the cells.
To experimentally verify this, the proviral DNAs NL4-3 and
NL-Vpr-FL were transfected into RD cells and the virus par-
ticles were collected between 72^120 h after transfection. The
Fig. 3. Immunoblot analysis of virus particles derived from trans-
fected cells using antibodies against Flag epitope. Equal amounts of
virus lysate, normalized on the basis of p24 antigen values, were
separated on SDS^PAGE. M, molecular weight markers (kDa);
lane 1, pCDNA3 ; lane 2, NLvVpr+Vpr E21,24P-FL; lane 3,
NLvVpr+Vpr-FL. Arrow indicates Vpr-FL.
Fig. 4. Hypothetical scenarios for the extent of incorporation of
Vpr into the virus particles.
Fig. 5. A: Immunoblot analysis of virus particles derived from the
DNA transfected cells using antibodies against Flag epitope. The vi-
rus particles were harvested 120 h after transfection and virus ly-
sates normalized on the basis of p24 antigen values were loaded on
the gel. M, molecular weight markers (kDa); lane 1, NL-Vpr-FL;
lane 2, NL-Vpr-FL+Vpr-FL; lane 3, NL-Vpr-FL+Vpr; lane 4,
NL4-3. B: Densitometric analysis of Vpr-FL in the virus particles.
the data represent the average of two independent experiments as
described.
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viral lysate, upon p24 antigen assay, was subjected to immu-
noblot analysis using Flag antibodies. The results showed a
band corresponding to Vpr-FL in the virus particles derived
from NL-Vpr-FL and not from cells transfected with NL4-3.
The incorporation level of Vpr-FL, as shown in Fig. 5A, is
low when expressed in the context of proviral DNA. How-
ever, the virus particles derived from co-transfection of NL-
Vpr-FL and the Vpr-FL expression plasmid showed an in-
tense Vpr-FL band in comparison to NL-Vpr-FL suggesting
that the amount of Vpr-FL incorporated into the virus par-
ticles is £exible.
To address the speci¢city and competition between Vpr
molecules, co-transfection of NL-Vpr-FL with the Vpr wild-
type expression plasmid (lacking the Flag epitope) was carried
out. It was reasoned that the incorporation of Vpr without the
Flag epitope will reduce the signal observed for Vpr-FL in-
corporated into the virus particles. The immunoblot analysis
of virus particles revealed a less intense band in support of
this (Fig. 5A, lane 3).
The densitometric analysis of the immunoblot signals, upon
normalization based on p24 antigen values, showed a 20-fold
increase in the incorporation of Vpr-FL in co-transfection
experiments in comparison to NL-Vpr-FL alone (Fig. 5B).
Such an analysis involving virus particles derived from NL-
Vpr-FL and a Vpr expression plasmid showed a signal which
was 45% less than that of NL-Vpr-FL.
These results support the hypothesis that at least one of the
limiting factors in the level of incorporation of Vpr-FL is the
amount of Vpr-FL present within cells. This conclusion was
also supported by the analysis of virus particles derived from
co-transfection of NLvVpr which lacks the ability to synthe-
size Vpr, and Vpr-FL expression plasmids. The expression of
Vpr-FL, in trans, resulted in an enhanced incorporation of
Vpr-FL within the virus particles (Fig. 6), in comparison to
the virus from NL-Vpr-FL.
4. Discussion
The studies described here provide evidence that one of the
contributing factors underlying the incorporation of non-
structural proteins such as Vpr into the virus particles is the
level of expression of the protein within the cell. The increased
level of expression of Vpr correlated with its enhanced incor-
poration into the virus particles. Vpr, one of the three auxil-
iary proteins present inside the virus particles, is regulated by
Rev [10,28]. It is likely that the low amount of Vpr noted
within the virus particles derived from NL-Vpr-FL is a con-
sequence of the low level of Vpr present within cells. A related
issue that needs to be addressed is whether the extent of in-
corporation of a non-structural protein is ¢xed or £exible in
regards to the amount of structural protein Gag (Fig. 4). Co-
transfection of HIV-1 proviral DNA containing Vpr-FL with
the Vpr-FL expression plasmid was carried out to derive the
virus particles for the analysis. An enhanced incorporation of
Vpr-FL was detected by immunoblot analysis of virus par-
ticles and such an increase was not noted when pCDNA3
DNA was used for co-transfection. The increased Vpr-FL
incorporation was dependent upon the concentration of the
expression plasmid used for co-transfection (data not shown).
Though incorporation of Vpr into the virus particles has
been noted by several investigators, the underlying mechanism
involved remains unclear [9,10,14,15,30,31,34,40,47,53]. In this
regard, clearly the amount of Vpr present in relation to Gag
in the virus particles may provide clues as to a possible mech-
anism(s). Studies reported in the literature suggested that di-
rect interaction between Vpr and Gag may be responsible for
the incorporation of Vpr into the virus particles. Lavellee et
al. [27] provided evidence in support of the interaction of Gag
and Vpr in cells. Recently, interactions between Vpr and p17
was noted in a yeast two-hybrid system [41]. Similarly, Vpr
interactions with NCp7 was also reported [11,46]. Though
these studies showed an interaction of Vpr with processed
components of the Gag precursor Pr55, it remains to be dem-
onstrated whether such interactions exist involving the precur-
sor protein. This is important in light of the fact that both
NMR and crystallographic studies of matrix and capsid of
HIV-1 Gag suggest conformational changes upon cleavage
of the precursor protein [19^22].
With respect to the incorporation of non-structural pro-
teins, the number of molecules present in the virion has
been estimated for Vif (7^100 molecules) [2,4,19,29] and Nef
(5^20 molecules) [49]. The information for Vpr is less clear.
The epitope-tagging approach considered here has revealed
the following new information: (i) the number of molecules
of Vpr incorporated into the virus particles is not rigid, (ii)
incorporation of Vpr can be modulated by the level of Vpr in
cells, (iii) extent of incorporation of Vpr into the virus par-
ticles is directly proportional to the level of expression in cells,
(iv) co-transfection of NLvVpr and Vpr-FL expression plas-
mids also showed an enhanced incorporation of Vpr-FL into
the virus particles in comparison to the expression of Vpr-FL
in the context of proviral DNA, and (v) the inclusion of a Vpr
mutant (Vpr E21,24P-FL), which exhibits a negative virion
incorporation phenotype, in co-transfection experiments using
NLvVpr indicated that increased Vpr-FL was not due to non-
speci¢c association with the virus particles.
In addition to providing information regarding the incor-
poration level of Vpr when expressed in cis or trans, the re-
sults generated here have a bearing on the stoichiometry of
the proteins in the virus particles. Analysis of HIV-1 particles
has led to the suggestion that there are 2750 molecules of Gag
present in a virion [1]. Gag-pol protein generated by a ribo-
somal frameshifting mechanism was estimated to be 10^20-
fold less than that of Gag in the virus particles [8]. While
the amount of structural proteins (both Gag and Gag-pol)
present in the virus particles is rigid with respect to the num-
ber, the results obtained for Vpr in this study suggest a £ex-
ible mode regarding the incorporation of non-structural pro-
teins into the virus particles. Recently, a similar scenario was
reported for Vif [44]. However, the di¡erence between Vif and
Vpr is that the former utilizes a non-speci¢c mechanism for its
incorporation into the virus particles. It is unclear at this time
whether the number of molecules of Nef is rigid or £exible.
Fig. 6. Immunoblot analysis of virus particles using antibodies
against Flag epitope. M, molecular weight markers (kDa); lane 1,
NLvVpr; lane 2, NLvVpr+Vpr-FL; lane 3, Vpr-FL (positive con-
trol). An equal amount of viral lysate based on p24 antigen was
loaded.
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This information may help to draw a general conclusion that
the rules for the incorporation of non-structural proteins into
the virus particles are di¡erent from the structural proteins.
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